Asset Management One Co. Ltd. Boosts Stock Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Asset Management One Co. Ltd. lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 250,089 shares of the medical research company’s stock after acquiring an additional 8,271 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $18,126,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of EW. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $27,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Global X Japan Co. Ltd. increased its position in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after acquiring an additional 216 shares during the period. Finally, ORG Wealth Partners LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EW. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, April 25th. Dbs Bank upgraded shares of Edwards Lifesciences to a “hold” rating in a research note on Monday, June 2nd. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 13th. Truist Financial lowered their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $80.20.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer now owns 41,098 shares in the company, valued at $3,057,691.20. This trade represents a 21.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of Edwards Lifesciences stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the transaction, the chief executive officer now owns 58,284 shares in the company, valued at approximately $4,366,054.44. This trade represents a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,648 shares of company stock valued at $2,998,866 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 1.5%

Shares of Edwards Lifesciences stock opened at $76.95 on Thursday. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $75.38 and a two-hundred day moving average of $73.08. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $95.25. The stock has a market cap of $45.14 billion, a PE ratio of 10.99, a price-to-earnings-growth ratio of 3.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period last year, the company posted $0.66 EPS. The company’s revenue was up 6.2% on a year-over-year basis. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.